The UK has halted a trial of a controversial anti-malarial drug that was initially thought to prevent COVID-19. The trial was halted after scientists found that there was 'no evidence of benefit.' Professor Peter Horby and Professor Martin Landray, chief investigators of the RECOVERY trial, said: "In March this year, RECOVERY was established as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. "The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK.
Throughout this time, the independent Data Monitoring Committee has reviewed the emerging data about every two weeks to determine if there is evidence that would be strong enough to